Who was studied, and how
Four numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 23 other studies
226people in the Effect of Liraglutide on Glycaemic Control in Japanese Subjects With Type 2 Diabetes. trial, from 2005
of them with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
liraglutide (dose not specified, but implied up to 0.9mg/day)
placebo
Reported lower fasting blood sugar, no range given−2.50
Reported lower postprandial glucose excursion, no range given−12.8
Reported higher postprandial insulin secretion, no range given+23.0
randomisedthe abstract, start to end
… placebo: fasting plasma glucose (up to 2.5mmol/L), postprandial (0-3h) glucose excursion (up to 12.8mmol/(Lh)); and increased postprandial insulin secretion (up to 23.0microU/(mLh)) and beta-cell function as evaluated by HOMA-beta (up to around 20.0(microU/mL)/(mg/dL)).
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Fasting plasma glucoseliraglutide (dose not specified, but implied up to 0.9mg/day) vs placebo
−2.50
Postprandial (0-3h) glucose excursionliraglutide (dose not specified, but implied up to 0.9mg/day) vs placebo
−12.8
Postprandial insulin secretionliraglutide (dose not specified, but implied up to 0.9mg/day) vs placebo
23.0
Beta-cell function as evaluated by HOMA-betaliraglutide (dose not specified, but implied up to 0.9mg/day) vs placebo
20.0
GLP-1 receptor agonistsGlycemic control
GLP-1 receptor agonists × glycemic controlhelps?replicated
unlikelylikely
0.910.91 without it
← favours comparatorfavours treatment →
1 / 7